Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575192 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
A Phase 3 study of Breast Reconstruction, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 783
- Enrollment target
- 20
- Study locations
NCT06575192: Recruiting Phase 3 study of Breast Reconstruction, sponsored by AbbVie.
NCT06575192 is a Phase 3 study of Breast Reconstruction that is actively recruiting participants, run by AbbVie. The registered enrollment target is 783 participants, above the 350-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (124% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06575192, a Phase 3 study of Breast Reconstruction, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 783 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.
Primary Outcome
Number of participants with at least one major complication related to breast reconstruction.
Conditions Studied
Interventions
- OTHER No Intervention
- DEVICE ARTIA Reconstructive Tissue Matrix
Study Locations (20)
California
- Cedars-Sinai Medical Center /ID# 268326 - Los Angeles
- UC Irvine Medical Center /ID# 267428 - Orange
- Stanford University Medical Center CTRU - 800 Welch Road /ID# 264196 - Palo Alto
- South Bay Plastic Surgeons /ID# 264192 - Torrance
Illinois
- Rush University Medical Center /ID# 275935 - Chicago
- Endeavor Health /ID# 266302 - Northbrook
New York
- Northwell Health Clinical Trials Office /ID# 268076 - Lake Success
- NYU Langone Medical Center /ID# 265621 - New York
Tennessee
- Erlanger Health System /ID# 266608 - Chattanooga
- East Tennessee State University /ID# 264321 - Johnson City
Colorado
- University Of Colorado - Anschutz Medical Campus /ID# 268627 - Aurora
Florida
- University of Florida College of Medicine /ID# 267485 - Gainesville
Maryland
- Johns Hopkins Hospital /ID# 265917 - Baltimore
Missouri
- Washington University School of Medicine - St. Louis /ID# 264029 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 783 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2029-12 |
| Phase | Phase 3 |
What NCT06575192 shows while recruiting
NCT06575192 is an interventional study that assigns participants to a tested intervention. The registered 783 participants enrollment target is mid-sized for trials with a published cap, above the 350-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (124% higher).
The record links to 1 condition, with Breast Reconstruction appearing as the primary indexed condition, and to 2 interventions - of which No Intervention is the first listed.
NCT06575192 names 20 study sites across 14 states, led by California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT06575192 about?
NCT06575192 is a clinical study titled "Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants". The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.
What is the current status of trial NCT06575192?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 783 participants. The study started on 2024-11-05. Estimated completion is 2029-12.
What conditions does trial NCT06575192 study?
This clinical trial studies the following conditions: Breast Reconstruction.
What interventions are being tested in trial NCT06575192?
The interventions under investigation include: No Intervention (OTHER), ARTIA Reconstructive Tissue Matrix (DEVICE).
Who is sponsoring clinical trial NCT06575192?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06575192 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Reconstruction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06575192's enrollment target sits among peer trials
783 3rd of 18 higher than 16 of 18 other Breast Reconstruction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Reconstruction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study)
COMPLETED · Phase 3
-
Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial
COMPLETED · Phase 3
-
A Study on Pain After Breast Reconstruction
RECRUITING · NA
-
Melodi Matrix™ in Breast Reconstruction
RECRUITING · NA
-
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
RECRUITING · NA
-
Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06118723 · 784 participants
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- NCT06498128 · 785 participants
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
- NCT07276724 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
- NCT07359846 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI